Literature DB >> 18567667

Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones.

Andreas Mueller1, Louis Gooren.   

Abstract

OBJECTIVE: To assess the risk of development of hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Design Description of cases of transsexuals who have developed a hormone-related malignancy observed in their own clinic or reported in the literature. Recommendations for early diagnosis and prevention are presented.
METHODS: Review of the literature in PubMed.
RESULTS: In male-to-female transsexuals receiving estrogen administration, lactotroph adenomas, breast cancer, and prostate cancer have been reported. In female-to-male transsexuals receiving treatment with testosterone, a single case of breast carcinoma and several cases of ovarian cancer have been reported. So far endometrial cancer has not been encountered though it remains a potential malignant development.
CONCLUSIONS: There are so far only a few cases of hormone-related cancer in transsexuals. There may be an underreporting. The probability of a hormone-related tumor increases with the duration of exposure to cross-sex hormones and the aging of the population of transsexuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18567667     DOI: 10.1530/EJE-08-0289

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  26 in total

1.  SIAMS-ONIG Consensus on hormonal treatment in gender identity disorders.

Authors:  A Godano; M Maggi; E Jannini; M C Meriggiola; E Ghigo; O Todarello; A Lenzi; C Manieri
Journal:  J Endocrinol Invest       Date:  2009-11       Impact factor: 4.256

Review 2.  Nongenomic signaling pathways of estrogen toxicity.

Authors:  Cheryl S Watson; Yow-Jiun Jeng; Mikhail Y Kochukov
Journal:  Toxicol Sci       Date:  2009-12-02       Impact factor: 4.849

Review 3.  An overview of female-to-male gender-confirming surgery.

Authors:  Shane D Morrison; Mang L Chen; Curtis N Crane
Journal:  Nat Rev Urol       Date:  2017-05-16       Impact factor: 14.432

Review 4.  Gender reassignment surgery: an overview.

Authors:  Gennaro Selvaggi; James Bellringer
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

Review 5.  Cross-sex hormone therapy for gender dysphoria.

Authors:  B Fabris; S Bernardi; C Trombetta
Journal:  J Endocrinol Invest       Date:  2014-11-18       Impact factor: 4.256

Review 6.  Cancer in Transgender People: Evidence and Methodological Considerations.

Authors:  Hayley Braun; Rebecca Nash; Vin Tangpricha; Janice Brockman; Kevin Ward; Michael Goodman
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

7.  Breast cancer risk and breast screening for trans people: an integration of 3 systematic reviews.

Authors:  Olivia Meggetto; Leslea Peirson; Mafo Yakubu; Mufiza Farid-Kapadia; Michelle Costa-Fagbemi; Shamara Baidoobonso; Jessica Moffatt; Lauren Chun; Anna M Chiarelli; Derek Muradali
Journal:  CMAJ Open       Date:  2019-10-01

Review 8.  Endocrine treatment of aging transgender people.

Authors:  Louis J Gooren; Guy T'Sjoen
Journal:  Rev Endocr Metab Disord       Date:  2018-09       Impact factor: 6.514

9.  Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels.

Authors:  Petteri Ahtiainen; Victoria Sharp; Susana B Rulli; Adolfo Rivero-Müller; Veronika Mamaeva; Matias Röyttä; Ilpo Huhtaniemi
Journal:  Endocr Relat Cancer       Date:  2010-06-03       Impact factor: 5.678

Review 10.  Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention.

Authors:  James D Shull; Kirsten L Dennison; Aaron C Chack; Amy Trentham-Dietz
Journal:  Physiol Genomics       Date:  2018-01-26       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.